Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Citicoline as Neuroprotector in Preterm
NCT03966170Phase 3Recruiting
- Start
- May 2019
- Primary completion
- Nov 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, triple-blind trial in traumatic brain injury (TBI) comparing Citicoline with Placebo (2 arms). Primary endpoint: Number of children with affection of the brain at 6 months. Started May 2019; status: recruiting.
02
Drugs
citicoline
03
Conditions
traumatic brain injury (TBI)
Beyond the preview
Go deeper on NCT03966170.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03966170.